The evidence that TB5, more than KPL-1, was able to kill ALCL cell lines prompted us to develop fully human or chimeric recombinant antibodies against PSGL1 in order to fully exploit the induction of CDC but also ADCC and phagocytosis. This evidence concerns the gene TBRG1 and anaplastic large cell lymphoma.